Status:

UNKNOWN

Influence of HLA-DQA1*05 Genotype in Adults With Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring.

Lead Sponsor:

Hospital del Rio Hortega

Collaborating Sponsors:

Francisco Javier Garcia Alonso

Jesús Barrio

Conditions:

Drug Monitoring

Inflammatory Bowel Diseases

Eligibility:

All Genders

18+ years

Brief Summary

HLA-DQA1\*05 variant carriers are at risk of developing antibodies against infliximab and adalimumab with reduced TNF antagonist persistence. The impact of proactive therapeutic drug monitoring (PTDM...

Detailed Description

Population study: patients with inflammatory bowel disease and initiation of anti-TNF therapy Inclusion and exclusion criteria The inclusion criteria are: * Patient diagnosed with inflammatory bowe...

Eligibility Criteria

Inclusion

  • Diagnosis of inflammatory bowel disease according to ECCO criteria.
  • Older than 18 years
  • Subjects naïve to biological treatment
  • Anti-TNF treatment initiation (infliximab or adalimumab) due to intestinal activity and/or perianal disease.
  • Avaibility to evaluate HLA DQA1\*05 status
  • Proactive therapeutic drug monitoring of anti-TNF levels

Exclusion

  • Initiation of anti-TNF treatment as prevention of post-surgical recurrence in Crohn's disease during the first 12 months after surgery or, afterwards, if endoscopic recurrence with a Rutgeerts 0-1.
  • Initiation of anti-TNF treatment under combo treatment with immunomodulator. Prior initiation of immunomodulator or prior use and suspension would not be a contraindication.
  • Initiation of anti-TNF treatment due to extraintestinal activity.
  • Initiation of anti-TNF treatment by a non-gastroenterologist specialist.
  • Initiation of anti-TNF treatment during pregnancy.

Key Trial Info

Start Date :

January 11 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

January 1 2025

Estimated Enrollment :

280 Patients enrolled

Trial Details

Trial ID

NCT05986903

Start Date

January 11 2023

End Date

January 1 2025

Last Update

August 14 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital Universitario Rio Hortega

Valladolid, Spain

Influence of HLA-DQA1*05 Genotype in Adults With Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring. | DecenTrialz